{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:39:10Z","timestamp":1786984750505,"version":"build-2736575974"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ageing Research Reviews"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.arr.2023.102018","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T13:41:45Z","timestamp":1689860505000},"page":"102018","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways"],"prefix":"10.1016","volume":"90","author":[{"given":"Francesca","family":"Mancinetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionysios","family":"Xenos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelantonio","family":"De Fano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Mazzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Porcellati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2134-1122","authenticated-orcid":false,"given":"Virginia","family":"Boccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Mecocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arr.2023.102018_bib1","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2337\/dc09-2030","article-title":"Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment","volume":"33","author":"Abbatecola","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.102018_bib2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s12272-020-01237-y","article-title":"Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway","volume":"43","author":"Abdel-latif","year":"2020","journal-title":"Arch. Pharm. Res"},{"key":"10.1016\/j.arr.2023.102018_bib3","unstructured":"Alzheimer\u2019s Facts and Figures Report | Alzheimer\u2019s Association [WWW Document], 2022. URL \u3008https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures\u3009 (accessed 7.14.23)."},{"key":"10.1016\/j.arr.2023.102018_bib4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2023.102018_bib5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","article-title":"Canagliflozin prevents scopolamine-induced memory impairment in rats: comparison with galantamine hydrobromide action","volume":"277","author":"Arafa","year":"2017","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.arr.2023.102018_bib6","doi-asserted-by":"crossref","unstructured":"Barone, E., Giaccari, A., Duarte, J.M.N., Fusco, S., Spinelli, M., Grassi, C., 2019. Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline. https:\/\/doi.org\/10.3389\/fnins.2019.00788.","DOI":"10.3389\/fnins.2019.00788"},{"key":"10.1016\/j.arr.2023.102018_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","article-title":"Brain-derived neurotrophic factor and its clinical implications","volume":"11","author":"Bathina","year":"2015","journal-title":"Arch. Med Sci."},{"key":"10.1016\/j.arr.2023.102018_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104542","article-title":"Doxorubicin and its proarrhythmic effects: a comprehensive review of the evidence from experimental and clinical studies","volume":"151","author":"Benjanuwattra","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.arr.2023.102018_bib9","first-page":"54","article-title":"Diabetes drugs in the fight against Alzheimer\u2019s disease","author":"Boccardi","year":"2019","journal-title":"Ageing Res Rev."},{"key":"10.1016\/j.arr.2023.102018_bib10","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI57256","article-title":"An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer\u2019s disease- associated A\u03b2 oligomers","volume":"122","author":"Bomfim","year":"2012","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.arr.2023.102018_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mehy.2017.06.024","article-title":"Brain-derived neurotrophic factor mediates cognitive improvements following acute exercise","volume":"106","author":"Borror","year":"2017","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.arr.2023.102018_bib12","first-page":"13","article-title":"The effects of insulin on the inflammatory activity of BV2 microglia","author":"Brabazon","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.arr.2023.102018_bib13","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.arr.2023.102018_bib14","first-page":"3","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.arr.2023.102018_bib15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.102018_bib16","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/joim.12287","article-title":"Heart failure and Alzheimer\u2019s disease","volume":"277","author":"Cermakova","year":"2015","journal-title":"J. Intern Med"},{"key":"10.1016\/j.arr.2023.102018_bib17","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.tins.2022.03.001","article-title":"Insulin action in the brain: cell types, circuits, and diseases","volume":"45","author":"Chen","year":"2022","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.arr.2023.102018_bib18","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12020-017-1301-x","article-title":"Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors-overlooked and overwhelming? A retrospective case series","volume":"59","author":"Chilelli","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.arr.2023.102018_bib19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejphar.2013.08.008","article-title":"Insulin, cognition, and dementia","volume":"719","author":"Cholerton","year":"2013","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.arr.2023.102018_bib20","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"Defronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.102018_bib21","first-page":"3","article-title":"Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review","author":"Desouza","year":"2010","journal-title":"Clin. Med Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.arr.2023.102018_bib22","first-page":"1","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","author":"Deture","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.arr.2023.102018_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ana.22055","article-title":"Atherosclerosis, dementia, and alzheimer\u2019s disease in the BLSA cohort","volume":"68","author":"Dolan","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.arr.2023.102018_bib24","first-page":"13","article-title":"The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease","author":"Du","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.arr.2023.102018_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00784-w","article-title":"Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer\u2019s subjects","volume":"13","author":"Femminella","year":"2021","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.102018_bib26","first-page":"23","article-title":"Obesity as a risk factor for dementia and Alzheimer\u2019s disease: the role of leptin","author":"Flores-Cordero","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.102018_bib27","first-page":"12","article-title":"The role of leptin and adiponectin in obesity-associated cognitive decline and Alzheimer\u2019s disease","author":"Forny-Germano","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.102018_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101236","article-title":"Insulin\u2019s actions on vascular tissues: physiological effects and pathophysiological contributions to vascular complications of diabetes","volume":"52","author":"Fu","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.arr.2023.102018_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of Type 2 Diabetes Mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.102018_bib30","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.arr.2023.102018_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1107-y","article-title":"Epidemiology of diabetes mellitus and cardiovascular disease","volume":"21","author":"Glovaci","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.arr.2023.102018_bib32","first-page":"13","article-title":"Glucagon-like peptide-1: a focus on neurodegenerative diseases","author":"Grieco","year":"2019","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.102018_bib33","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -\/- mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.arr.2023.102018_bib34","first-page":"9","article-title":"Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db\/db mouse","author":"Hayden","year":"2019","journal-title":"Brain Sci."},{"key":"10.1016\/j.arr.2023.102018_bib35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.arr.2023.102018_bib36","first-page":"12","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimers Res Ther."},{"key":"10.1016\/j.arr.2023.102018_bib37","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.diabres.2017.11.016","article-title":"Increased sugar intake as a form of compensatory hyperphagia in patients with type 2 diabetes under dapagliflozin treatment","volume":"135","author":"Horie","year":"2018","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.arr.2023.102018_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on SGLT2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.arr.2023.102018_bib39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3233\/JAD-2011-101524","article-title":"Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin","volume":"24","author":"Hsu","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102018_bib40","doi-asserted-by":"crossref","first-page":"9846","DOI":"10.3390\/ijms24129846","article-title":"Dementia in diabetes: the role of hypoglycemia","volume":"24","author":"Husain","year":"2023","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.102018_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.4103\/japtr.JAPTR_317_18","article-title":"Sulfonylurea and neuroprotection: the bright side of the moon","volume":"9","author":"Hussien","year":"2018","journal-title":"J. Adv. Pharm. Technol. Res"},{"key":"10.1016\/j.arr.2023.102018_bib42","first-page":"8","article-title":"The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes","author":"Iannantuoni","year":"2019","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.arr.2023.102018_bib43","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.3390\/ijms22063062","article-title":"Unexpected pleiotropic effects of SGLT2 inhibitors: pearls and pitfalls of this novel antidiabetic class","volume":"Vol. 22","author":"Kaneto","year":"2021","journal-title":"Int. J. Mol. Sci. 2021"},{"key":"10.1016\/j.arr.2023.102018_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.arr.2023.102018_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114945","article-title":"Metformin in Alzheimer\u2019s disease: an overview of potential mechanisms, preclinical and clinical findings","volume":"197","author":"Khezri","year":"2022","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.arr.2023.102018_bib46","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.arr.2023.102018_bib47","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/db14-0568","article-title":"Insulin action in brain regulates systemic metabolism and brain function","volume":"63","author":"Kleinridders","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.arr.2023.102018_bib48","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer\u2019s disease","volume":"72","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.arr.2023.102018_bib49","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1734-1140(10)70357-1","article-title":"Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide","volume":"62","author":"\u0141abuzek","year":"2010","journal-title":"Pharm. Rep."},{"key":"10.1016\/j.arr.2023.102018_bib50","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1037\/0735-7044.112.5.1199","article-title":"Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats","volume":"112","author":"Lannert","year":"1998","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.arr.2023.102018_bib51","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann. Transl. Med"},{"key":"10.1016\/j.arr.2023.102018_bib52","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.arr.2023.102018_bib53","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer\u2019s disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharm. Biochem Behav."},{"key":"10.1016\/j.arr.2023.102018_bib54","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00125-005-1787-2","article-title":"Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: Role of protein kinase B","volume":"48","author":"Li","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.arr.2023.102018_bib55","first-page":"12","article-title":"Deciphering the roles of metformin in Alzheimer\u2019s disease: a snapshot","author":"Liao","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.arr.2023.102018_bib56","first-page":"13","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.arr.2023.102018_bib57","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","article-title":"Markers of kidney injury, inflammation, and fibrosis associated with ertugliflozin in patients with CKD and diabetes","volume":"6","author":"Liu","year":"2021","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.arr.2023.102018_bib58","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-019-0071-8","article-title":"Erratum: author correction: history and progress of hypotheses and clinical trials for Alzheimer\u2019s disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.arr.2023.102018_bib59","article-title":"Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes: a protocol for systematic review and meta analysis","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.arr.2023.102018_bib60","first-page":"20","article-title":"Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity","author":"Liu","year":"2021","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.arr.2023.102018_bib61","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.arr.2023.102018_bib62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.arr.2023.102018_bib63","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3233\/JAD-215678","article-title":"Association between use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes","volume":"87","author":"Low","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102018_bib64","first-page":"23","article-title":"Is metformin a perfect drug? Updates in pharmacokinetics and pharmacodynamics","author":"Markowicz-Piasecka","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.arr.2023.102018_bib65","first-page":"65","article-title":"The impact of aging in dementia: It is time to refocus attention on the main risk factor of dementia","author":"Mecocci","year":"2021","journal-title":"Ageing Res Rev."},{"issue":"5","key":"10.1016\/j.arr.2023.102018_bib66","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/ijms23052687","article-title":"Alzheimer's Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms between Alzheimer's Disease and Type 2 Diabetes","volume":"23","author":"Michailidis","year":"2022","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.arr.2023.102018_bib67","first-page":"8","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matched population-based study with competing risk analysis","author":"Mui","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.arr.2023.102018_bib68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/ajh.2009.212","article-title":"Hypertension and dementia","volume":"23","author":"Nagai","year":"2010","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.arr.2023.102018_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.arr.2023.102018_bib70","first-page":"21","article-title":"Type 3 diabetes and its role implications in Alzheimer\u2019s disease","author":"Nguyen","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.arr.2023.102018_bib71","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer\u2019s and Parkinson\u2019s disease","volume":"28","author":"Nowell","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.arr.2023.102018_bib72","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s11606-020-05895-y","article-title":"Age and incidence of dementia diagnosis","volume":"36","author":"Olfson","year":"2021","journal-title":"J. Gen. Intern Med"},{"key":"10.1016\/j.arr.2023.102018_bib73","first-page":"4","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.arr.2023.102018_bib74","first-page":"202","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.arr.2023.102018_bib75","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.lfs.2006.07.018","article-title":"Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats","volume":"79","author":"Pathan","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.arr.2023.102018_bib76","first-page":"26","article-title":"Neuroprotective effect of SGLT2 inhibitors","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.arr.2023.102018_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/JOE-12-0521","article-title":"DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats","volume":"218","author":"Pintana","year":"2013","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.arr.2023.102018_bib78","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.102018_bib79","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cns.12866","article-title":"Insulin receptor in the brain: Mechanisms of activation and the role in the CNS pathology and treatment","volume":"24","author":"Pomytkin","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.arr.2023.102018_bib80","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.freeradbiomed.2010.12.006","article-title":"Oxidative stress, insulin signaling, and diabetes","volume":"50","author":"Rains","year":"2011","journal-title":"Free Radic. Biol. Med"},{"key":"10.1016\/j.arr.2023.102018_bib81","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.arr.2023.102018_bib82","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1517\/14656566.9.7.1087","article-title":"Pleiotropic effects of thiazolidinediones","volume":"9","author":"Rizos","year":"2008","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.arr.2023.102018_bib83","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/gerona\/glu032","article-title":"Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment","volume":"69","author":"Rizzo","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med Sci."},{"key":"10.1016\/j.arr.2023.102018_bib84","first-page":"176","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","author":"Rizzo","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.arr.2023.102018_bib85","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.arr.2023.102018_bib86","first-page":"1093","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Rosenstein","year":"2016","journal-title":"New Engl. J. Med"},{"key":"10.1016\/j.arr.2023.102018_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000369101","article-title":"Amyloid-beta: a crucial factor in Alzheimer\u2019s disease","volume":"24","author":"Sadigh-Eteghad","year":"2015","journal-title":"Med. Princ. Pract."},{"key":"10.1016\/j.arr.2023.102018_bib88","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.arr.2023.102018_bib89","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2023.102018_bib90","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s40265-014-0298-1","article-title":"Empagliflozin: a review of its use in patients with type 2 diabetes mellitus","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.arr.2023.102018_bib91","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.arr.2023.102018_bib92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/bab.1319","article-title":"Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders","volume":"63","author":"Shaikh","year":"2016","journal-title":"Biotechnol. Appl. Biochem"},{"key":"10.1016\/j.arr.2023.102018_bib93","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2012.12.005","article-title":"Intracerebroventricular administration of an insulin analogue recovers STZ-induced cognitive decline in rats","volume":"241","author":"Shingo","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.arr.2023.102018_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.708547","article-title":"Role of DPP-4 and SGLT2 inhibitors connected to Alzheimer disease in type 2 diabetes mellitus","volume":"15","author":"Sim","year":"2021","journal-title":"Front Neurosci."},{"key":"10.1016\/j.arr.2023.102018_bib95","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: Molecular mechanisms and outcomes of a complex signaling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem Int"},{"key":"10.1016\/j.arr.2023.102018_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm9061713","article-title":"Link between diabetes and Alzheimer\u2019s disease due to the shared amyloid aggregation and deposition involving both neurodegenerative changes and neurovascular damages","volume":"9","author":"Stanciu","year":"2020","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.arr.2023.102018_bib97","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2105\/AJPH.2014.301935","article-title":"Characterization of dementia and Alzheimer\u2019s disease in an older population: updated incidence and life expectancy with and without dementia","volume":"105","author":"Tom","year":"2015","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.arr.2023.102018_bib98","first-page":"11","article-title":"Advanced glycation end-products (AGEs): formation, chemistry, classification, receptors, and diseases related to AGEs","author":"Twarda\u2010clapa","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.arr.2023.102018_bib99","first-page":"14","article-title":"Hypoglycemic medicines in the treatment of Alzheimer\u2019s disease: pathophysiological links between AD and glucose metabolism","author":"Wang","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.arr.2023.102018_bib100","first-page":"379","article-title":"Perspective of SGLT2 inhibition in treatment of conditions connected to neuronal loss: focus on Alzheimer\u2019s disease and ischemia-related brain injury","volume":"Vol. 13","author":"Wici\u0144ski","year":"2020","journal-title":"Pharmaceuticals 2020"},{"key":"10.1016\/j.arr.2023.102018_bib101","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamaneurol.2015.0613","article-title":"Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for alzheimer disease","volume":"72","author":"Willette","year":"2015","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.arr.2023.102018_bib102","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2337\/dc22-1705","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study","volume":"46","author":"Wu","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.arr.2023.102018_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/jgs.18397","article-title":"Association of sulfonylureas with the risk of dementia: A population-based cohort study","author":"Wu","year":"2023","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.arr.2023.102018_bib104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med"}],"container-title":["Ageing Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568163723001770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:18:03Z","timestamp":1761592683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568163723001770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":104,"alternative-id":["S1568163723001770"],"URL":"https:\/\/doi.org\/10.1016\/j.arr.2023.102018","relation":{},"ISSN":["1568-1637"],"issn-type":[{"value":"1568-1637","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways","name":"articletitle","label":"Article Title"},{"value":"Ageing Research Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arr.2023.102018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102018"}}